Background and Aims: Nintedanib, an oral tyrosine kinase inhibitor, has been shown to slow down the progression of idiopathic pulmonary fibrosis (IPF) in two randomised placebo-controlled trials by reducing the annual decline in forced vital capacity (FVC). However, data on the efficacy and safety of nintedanib for idiopathic pulmonary fibrosis is not sufficient.
effects, and so on, of nintedanib in 6 patients with IPF who were interventionally treated with nintedanib from October 2015 to May 2018.
Results: There are 6 subjects, male/female = 4 cases 2 cases, average age 70.3 years old, GAP index I/II/III/unknown = 0 cases/4 cases/1 case/1 case, %FVC 57.6 AE 12.9%, %DLCO 33.5 AE 11.6%, and KL-6 1399 AE 948 U/mL.
Four cases were discontinued, the reason for stopping was 2 cases of anorexia/1 case of liver function disorder, 1 case of blood sputum, and restarted in 2 cases. In addition, there was one case in which we continued oral administration after weight loss. One case was seen in which Nintedanib's involvement died of onset of kidney failure that cannot be denied. 3 cases improved %FVC, 4 cases showed a decrease in KL-6.
Conclusion:
There is a possibility that improvement of %FVC, KL-6 decrease can be expected by Nintedanib in some special cases which is a part of many IPF patients. However, when using nintedanib, adequate caution is required for the occurrence of adverse events. We will analyze and report in more detail at the 23rd Congress of the APSR. Results: There were 20 referrals with diagnosis of IPF ( M:F = 12:8 ) with mean age of 53.4 years (range 37 to 62). Majority of patients were referred for LT evaluation in a late stage of disease with 75% being oxygen dependent and 70% in New York Heart Association Class 3 or 4).
One patient went abroad for LT soon after seen. Eleven out of the remaining 19 patients managed to complete evaluation for LT while 8 patients died during evaluation. Two were excluded from LT due to medical reasons. Four received LT ultimately with waiting time ranging from 1 to 296 days. Mortality on waiting list was 55.5%. All 5 patients who received LT were alive ( 7 to 40 months from LT ) and enjoying good lung functions.
Of the 13 potential recipients who did not receive LT, all but 1 died. The mean time from referral for LT evaluation to death was 6.0 months (range 0.5 to 13). The mean waiting time for LT in Hong Kong was 11.47 months (2007 to 2016, unpublished data).
The high waiting list mortality (55.5%) and short survival from referral to death (mean 6.0 months) for IPF patients in Hong Kong reflected the local contemporary situation of scarcity of donors and late referrals. As LT confers survival benefit, early referral and strategies in expanding the lung donor pool might help the present unfavourable situation. 
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Background and Aims: Respiratory bronchiolitis-associated interstitial lung disease(RB-ILD) is a syndrome of small airway inflammation and interstitial lung disease occurring in smokers. Most smokers develop a subclinical bronchiolitis but a few patients who develop more severe inflammation with clinically significant interstitial lung disease are said to have RB-ILD. The clinical presentation resembles those of patients with other interstitial lung diseases-cough and dyspnea, with coarse rales on physical examination. Diffuse fine reticulonodular interstitial opacities are found on chest radiograph, usually with normal-appearing volumes. Histologically it is characterized by patchy and non-uniform accumulation of finely pigmented tan brown macrophages within membranous, terminal and respiratory bronchioles.
Methods:
We present the case of a 57 year-old, Taiwanese man, a cigarette smoker consuming 1 pack per day for 30 years, with history of chronic obstructive pulmonary disease that presented with productive cough, progressive dyspnea, body weight loss, and generalized weakness for one month. Chest X-ray and chest CT scan were done. Videoassisted thoracic surgery was done with right upper lobe wedge resection.
Results: On lung biopsy, pigment-laden macrophages are found within alveoli, and peribronchial inflammation noted.
Conclusion: Treatment of respiratory bronchiolitis-associated interstitial lung disease is smoking cessation and avoidance of even passive cigarette exposure, which may prevent improvement or lead to recurrence of the illness.
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